Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma

Sabrina Rossetti, Carmine D'Aniello, Gelsomina Iovane, Sarah Scagliarini, Maria M. Laterza, Fernando De Vita, Clementina Savastano, Giacomo Cartenì, Maria A. Porricelli, Massimiliano Berretta, Salvatore Pisconti, Gaetano Facchini, Carla Cavaliere

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In metastatic renal cell carcinoma, complete response to first-line antiangiogenic agents is rare and resistance to therapy often develops. Protocols for sequential treatment with angiogenesis and mTOR inhibitors are under evaluation to improve outcomes. In this observational, real-world study, patients received a first-line therapy with pazopanib until discontinuation for disease progression or toxicity, then a second-line with everolimus. Primary endpoints were overall survival (OS) for sequence, progression free survival (PFS) for each agent, and safety. Thirty-one patients were included in the analysis: 73.3% of patients underwent nephrectomy before treatment, 25.8% had at least three comorbidities. At the beginning of therapy, the median age was 68 years, with more than 60% of patients older than 65 years. The median OS for sequence was 26.5 months (95% CI 17.4-nc); median PFS was 10.6 months (95% CI 6.3-12.1) with pazopanib and 5.3 months (95% CI 3.8-6.7) with everolimus. The median persistence in pazopanib therapy was 8.1 months (Interquartile Range IQR 5.3-12.7), with 31% of patients who required dose reduction, while persistence in everolimus was 4.4 months (IQR 3.4-6.5). Sequence was well tolerated with a different profile of adverse events for each agent. These data confirmed that pazopanib was effective, even in reduced dosing, and well tolerated and suggested that everolimus may represent an opportunity to continue a therapy when patients cannot further tolerate angiogenesis inhibitors or develop a resistance.

Original languageEnglish
Article number484
JournalFrontiers in Pharmacology
Volume8
Issue numberJUL
DOIs
Publication statusPublished - Jul 20 2017

Fingerprint

Renal Cell Carcinoma
Angiogenesis Inhibitors
Disease-Free Survival
Therapeutics
Survival
Clinical Protocols
Nephrectomy
Disease Progression
Everolimus
pazopanib
Comorbidity
Safety

Keywords

  • Everolimus
  • Metastatic renal carcinoma
  • Pazopanib
  • Real-world
  • Sequential therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Rossetti, S., D'Aniello, C., Iovane, G., Scagliarini, S., Laterza, M. M., De Vita, F., ... Cavaliere, C. (2017). Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma. Frontiers in Pharmacology, 8(JUL), [484]. https://doi.org/10.3389/fphar.2017.00484

Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma. / Rossetti, Sabrina; D'Aniello, Carmine; Iovane, Gelsomina; Scagliarini, Sarah; Laterza, Maria M.; De Vita, Fernando; Savastano, Clementina; Cartenì, Giacomo; Porricelli, Maria A.; Berretta, Massimiliano; Pisconti, Salvatore; Facchini, Gaetano; Cavaliere, Carla.

In: Frontiers in Pharmacology, Vol. 8, No. JUL, 484, 20.07.2017.

Research output: Contribution to journalArticle

Rossetti, S, D'Aniello, C, Iovane, G, Scagliarini, S, Laterza, MM, De Vita, F, Savastano, C, Cartenì, G, Porricelli, MA, Berretta, M, Pisconti, S, Facchini, G & Cavaliere, C 2017, 'Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma', Frontiers in Pharmacology, vol. 8, no. JUL, 484. https://doi.org/10.3389/fphar.2017.00484
Rossetti S, D'Aniello C, Iovane G, Scagliarini S, Laterza MM, De Vita F et al. Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma. Frontiers in Pharmacology. 2017 Jul 20;8(JUL). 484. https://doi.org/10.3389/fphar.2017.00484
Rossetti, Sabrina ; D'Aniello, Carmine ; Iovane, Gelsomina ; Scagliarini, Sarah ; Laterza, Maria M. ; De Vita, Fernando ; Savastano, Clementina ; Cartenì, Giacomo ; Porricelli, Maria A. ; Berretta, Massimiliano ; Pisconti, Salvatore ; Facchini, Gaetano ; Cavaliere, Carla. / Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma. In: Frontiers in Pharmacology. 2017 ; Vol. 8, No. JUL.
@article{3748b315179944828bc68778e2f94b57,
title = "Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma",
abstract = "In metastatic renal cell carcinoma, complete response to first-line antiangiogenic agents is rare and resistance to therapy often develops. Protocols for sequential treatment with angiogenesis and mTOR inhibitors are under evaluation to improve outcomes. In this observational, real-world study, patients received a first-line therapy with pazopanib until discontinuation for disease progression or toxicity, then a second-line with everolimus. Primary endpoints were overall survival (OS) for sequence, progression free survival (PFS) for each agent, and safety. Thirty-one patients were included in the analysis: 73.3{\%} of patients underwent nephrectomy before treatment, 25.8{\%} had at least three comorbidities. At the beginning of therapy, the median age was 68 years, with more than 60{\%} of patients older than 65 years. The median OS for sequence was 26.5 months (95{\%} CI 17.4-nc); median PFS was 10.6 months (95{\%} CI 6.3-12.1) with pazopanib and 5.3 months (95{\%} CI 3.8-6.7) with everolimus. The median persistence in pazopanib therapy was 8.1 months (Interquartile Range IQR 5.3-12.7), with 31{\%} of patients who required dose reduction, while persistence in everolimus was 4.4 months (IQR 3.4-6.5). Sequence was well tolerated with a different profile of adverse events for each agent. These data confirmed that pazopanib was effective, even in reduced dosing, and well tolerated and suggested that everolimus may represent an opportunity to continue a therapy when patients cannot further tolerate angiogenesis inhibitors or develop a resistance.",
keywords = "Everolimus, Metastatic renal carcinoma, Pazopanib, Real-world, Sequential therapy",
author = "Sabrina Rossetti and Carmine D'Aniello and Gelsomina Iovane and Sarah Scagliarini and Laterza, {Maria M.} and {De Vita}, Fernando and Clementina Savastano and Giacomo Carten{\`i} and Porricelli, {Maria A.} and Massimiliano Berretta and Salvatore Pisconti and Gaetano Facchini and Carla Cavaliere",
year = "2017",
month = "7",
day = "20",
doi = "10.3389/fphar.2017.00484",
language = "English",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "JUL",

}

TY - JOUR

T1 - Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma

AU - Rossetti, Sabrina

AU - D'Aniello, Carmine

AU - Iovane, Gelsomina

AU - Scagliarini, Sarah

AU - Laterza, Maria M.

AU - De Vita, Fernando

AU - Savastano, Clementina

AU - Cartenì, Giacomo

AU - Porricelli, Maria A.

AU - Berretta, Massimiliano

AU - Pisconti, Salvatore

AU - Facchini, Gaetano

AU - Cavaliere, Carla

PY - 2017/7/20

Y1 - 2017/7/20

N2 - In metastatic renal cell carcinoma, complete response to first-line antiangiogenic agents is rare and resistance to therapy often develops. Protocols for sequential treatment with angiogenesis and mTOR inhibitors are under evaluation to improve outcomes. In this observational, real-world study, patients received a first-line therapy with pazopanib until discontinuation for disease progression or toxicity, then a second-line with everolimus. Primary endpoints were overall survival (OS) for sequence, progression free survival (PFS) for each agent, and safety. Thirty-one patients were included in the analysis: 73.3% of patients underwent nephrectomy before treatment, 25.8% had at least three comorbidities. At the beginning of therapy, the median age was 68 years, with more than 60% of patients older than 65 years. The median OS for sequence was 26.5 months (95% CI 17.4-nc); median PFS was 10.6 months (95% CI 6.3-12.1) with pazopanib and 5.3 months (95% CI 3.8-6.7) with everolimus. The median persistence in pazopanib therapy was 8.1 months (Interquartile Range IQR 5.3-12.7), with 31% of patients who required dose reduction, while persistence in everolimus was 4.4 months (IQR 3.4-6.5). Sequence was well tolerated with a different profile of adverse events for each agent. These data confirmed that pazopanib was effective, even in reduced dosing, and well tolerated and suggested that everolimus may represent an opportunity to continue a therapy when patients cannot further tolerate angiogenesis inhibitors or develop a resistance.

AB - In metastatic renal cell carcinoma, complete response to first-line antiangiogenic agents is rare and resistance to therapy often develops. Protocols for sequential treatment with angiogenesis and mTOR inhibitors are under evaluation to improve outcomes. In this observational, real-world study, patients received a first-line therapy with pazopanib until discontinuation for disease progression or toxicity, then a second-line with everolimus. Primary endpoints were overall survival (OS) for sequence, progression free survival (PFS) for each agent, and safety. Thirty-one patients were included in the analysis: 73.3% of patients underwent nephrectomy before treatment, 25.8% had at least three comorbidities. At the beginning of therapy, the median age was 68 years, with more than 60% of patients older than 65 years. The median OS for sequence was 26.5 months (95% CI 17.4-nc); median PFS was 10.6 months (95% CI 6.3-12.1) with pazopanib and 5.3 months (95% CI 3.8-6.7) with everolimus. The median persistence in pazopanib therapy was 8.1 months (Interquartile Range IQR 5.3-12.7), with 31% of patients who required dose reduction, while persistence in everolimus was 4.4 months (IQR 3.4-6.5). Sequence was well tolerated with a different profile of adverse events for each agent. These data confirmed that pazopanib was effective, even in reduced dosing, and well tolerated and suggested that everolimus may represent an opportunity to continue a therapy when patients cannot further tolerate angiogenesis inhibitors or develop a resistance.

KW - Everolimus

KW - Metastatic renal carcinoma

KW - Pazopanib

KW - Real-world

KW - Sequential therapy

UR - http://www.scopus.com/inward/record.url?scp=85025478324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025478324&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00484

DO - 10.3389/fphar.2017.00484

M3 - Article

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUL

M1 - 484

ER -